Seroatlas · Human Serome Atlas

PDZD2

PDZ domain-containing protein 2

Also known as: KIAA0300, PDZD2_HUMAN, PDZK3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O15018
Gene
PDZD2
Ensembl
ENSG00000133401
Chromosome
5
Canonical length
2839 aa
Protein class
Predicted intracellular proteins
Subcellular location
Plasma membrane,Cytosol
Secretome location
Intracellular and membrane

OverviewNCBI Gene

The protein encoded by this gene contains six PDZ domains and shares sequence similarity with pro-interleukin-16 (pro-IL-16). Like pro-IL-16, the encoded protein localizes to the endoplasmic reticulum and is thought to be cleaved by a caspase to produce a secreted peptide containing two PDZ domains. In addition, this gene is upregulated in primary prostate tumors and may be involved in the early stages of prostate tumorigenesis. [provided by RefSeq, Dec 2015]

Canonical amino-acid sequenceUniProt

2839 residues, UniProt reviewed canonical sequence.

>O15018|PDZD2
     1  MPITQDNAVL HLPLLYQWLQ NSLQEGGDGP EQRLCQAAIQ KLQEYIQLNF AVDESTVPPD
    61  HSPPEMEICT VYLTKELGDT ETVGLSFGNI PVFGDYGEKR RGGKKRKTHQ GPVLDVGCIW
   121  VTELRKNSPA GKSGKVRLRD EILSLNGQLM VGVDVSGASY LAEQCWNGGF IYLIMLRRFK
   181  HKAHSTYNGN SSNSSEPGET PTLELGDRTA KKGKRTRKFG VISRPPANKA PEESKGSAGC
   241  EVSSDPSTEL ENGPDPELGN GHVFQLENGP DSLKEVAGPH LERSEVDRGT EHRIPKTDAP
   301  LTTSNDKRRF SKGGKTDFQS SDCLAREEVG RIWKMELLKE SDGLGIQVSG GRGSKRSPHA
   361  IVVTQVKEGG AAHRDGRLSL GDELLVINGH LLVGLSHEEA VAILRSATGM VQLVVASKEN
   421  SAEDLLRLTS KSLPDLTSSV EDVSSWTDNE DQEADGEEDE GTSSSVQRAM PGTDEPQDVC
   481  GAEESKGNLE SPKQGSNKIK LKSRLSGGVH RLESVEEYNE LMVRNGDPRI RMLEVSRDGR
   541  KHSLPQLLDS SSASQEYHIV KKSTRSLSTT QVESPWRLIR PSVISIIGLY KEKGKGLGFS
   601  IAGGRDCIRG QMGIFVKTIF PNGSAAEDGR LKEGDEILDV NGIPIKGLTF QEAIHTFKQI
   661  RSGLFVLTVR TKLVSPSLTP CSTPTHMSRS ASPNFNTSGG ASAGGSDEGS SSSLGRKTPG
   721  PKDRIVMEVT LNKEPRVGLG IGACCLALEN SPPGIYIHSL APGSVAKMES NLSRGDQILE
   781  VNSVNVRHAA LSKVHAILSK CPPGPVRLVI GRHPNPKVSE QEMDEVIARS TYQESKEANS
   841  SPGLGTPLKS PSLAKKDSLI SESELSQYFA HDVPGPLSDF MVAGSEDEDH PGSGCSTSEE
   901  GSLPPSTSTH KEPGKPRANS LVTLGSHRAS GLFHKQVTVA RQASLPGSPQ ALRNPLLRQR
   961  KVGCYDANDA SDEEEFDREG DCISLPGALP GPIRPLSEDD PRRVSISSSK GMDVHNQEER
  1021  PRKTLVSKAI SAPLLGSSVD LEESIPEGMV DAASYAANLT DSAEAPKGSP GSWWKKELSG
  1081  SSSAPKLEYT VRTDTQSPTN TGSPSSPQQK SEGLGSRHRP VARVSPHCKR SEAEAKPSGS
  1141  QTVNLTGRAN DPCDLDSRVQ ATSVKVTVAG FQPGGAVEKE SLGKLTTGDA CVSTSCELAS
  1201  ALSHLDASHL TENLPKAASE LGQQPMTELD SSSDLISSPG KKGAAHPDPS KTSVDTGQVS
  1261  RPENPSQPAS PRVTKCKARS PVRLPHEGSP SPGEKAAAPP DYSKTRSASE TSTPHNTRRV
  1321  AALRGAGPGA EGMTPAGAVL PGDPLTSQEQ RQGAPGNHSK ALEMTGIHAP ESSQEPSLLE
  1381  GADSVSSRAP QASLSMLPST DNTKEACGHV SGHCCPGGSR ESPVTDIDSF IKELDASAAR
  1441  SPSSQTGDSG SQEGSAQGHP PAGAGGGSSC RAEPVPGGQT SSPRRAWAAG APAYPQWASQ
  1501  PSVLDSINPD KHFTVNKNFL SNYSRNFSSF HEDSTSLSGL GDSTEPSLSS MYGDAEDSSS
  1561  DPESLTEAPR ASARDGWSPP RSRVSLHKED PSESEEEQIE ICSTRGCPNP PSSPAHLPTQ
  1621  AAICPASAKV LSLKYSTPRE SVASPREKAA CLPGSYTSGP DSSQPSSLLE MSSQEHETHA
  1681  DISTSQNHRP SCAEETTEVT SASSAMENSP LSKVARHFHS PPIILSSPNM VNGLEHDLLD
  1741  DETLNQYETS INAAASLSSF SVDVPKNGES VLENLHISES QDLDDLLQKP KMIARRPIMA
  1801  WFKEINKHNQ GTHLRSKTEK EQPLMPARSP DSKIQMVSSS QKKGVTVPHS PPQPKTNLEN
  1861  KDLSKKSPAE MLLTNGQKAK CGPKLKRLSL KGKAKVNSEA PAANAVKAGG TDHRKPLISP
  1921  QTSHKTLSKA VSQRLHVADH EDPDRNTTAA PRSPQCVLES KPPLATSGPL KPSVSDTSIR
  1981  TFVSPLTSPK PVPEQGMWSR FHMAVLSEPD RGCPTTPKSP KCRAEGRAPR ADSGPVSPAA
  2041  SRNGMSVAGN RQSEPRLASH VAADTAQPRP TGEKGGNIMA SDRLERTNQL KIVEISAEAV
  2101  SETVCGNKPA ESDRRGGCLA QGNCQEKSEI RLYRQVAESS TSHPSSLPSH ASQAEQEMSR
  2161  SFSMAKLASS SSSLQTAIRK AEYSQGKSSL MSDSRGVPRN SIPGGPSGED HLYFTPRPAT
  2221  RTYSMPAQFS SHFGREGHPP HSLGRSRDSQ VPVTSSVVPE AKASRGGLPS LANGQGIYSV
  2281  KPLLDTSRNL PATDEGDIIS VQETSCLVTD KIKVTRRHYC YEQNWPHEST SFFSVKQRIK
  2341  SFENLANADR PVAKSGASPF LSVSSKPPIG RRSSGSIVSG SLGHPGDAAA RLLRRSLSSC
  2401  SENQSEAGTL LPQMAKSPSI MTLTISRQNP PETSSKGSDS ELKKSLGPLG IPTPTMTLAS
  2461  PVKRNKSSVR HTQPSPVSRS KLQELRALSM PDLDKLCSED YSAGPSAVLF KTELEITPRR
  2521  SPGPPAGGVS CPEKGGNRAC PGGSGPKTSA AETPSSASDT GEAAQDLPFR RSWSVNLDQL
  2581  LVSAGDQQRL QSVLSSVGSK STILTLIQEA KAQSENEEDV CFIVLNRKEG SGLGFSVAGG
  2641  TDVEPKSITV HRVFSQGAAS QEGTMNRGDF LLSVNGASLA GLAHGNVLKV LHQAQLHKDA
  2701  LVVIKKGMDQ PRPSARQEPP TANGKGLLSR KTIPLEPGIG RSVAVHDALC VEVLKTSAGL
  2761  GLSLDGGKSS VTGDGPLVIK RVYKGGAAEQ AGIIEAGDEI LAINGKPLVG LMHFDAWNIM
  2821  KSVPEGPVQL LIRKHRNSS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PDZD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0
Highest tissue expression
18 nTPM

Expression across tissuesHPA

Tissue

  • heart muscle: 18 nTPM
  • adipose tissue: 16 nTPM
  • retina: 14 nTPM
  • placenta: 10 nTPM
  • ovary: 9.8 nTPM
  • skin: 9.5 nTPM

Single-cell type

  • choroid plexus epithelial cells: 2,846 nCPM
  • proximal tubule cells: 1,410 nCPM
  • oligodendrocyte progenitor cells: 1,245 nCPM
  • cardiomyocytes: 876 nCPM
  • adipocytes: 798 nCPM
  • cone photoreceptor cells: 772 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • basal ganglia: 89 nTPM
  • cerebral cortex: 70 nTPM
  • choroid plexus: 61 nTPM
  • midbrain: 48 nTPM
  • medulla oblongata: 48 nTPM
  • amygdala: 46 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.28
gnomAD pLI
1
gnomAD missense Z
1.69
DepMap mean gene effect
0.05
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PDZD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PDZD2 as an antibody target. Whether an autoantibody or antibody against PDZD2 could matter depends on whether native PDZD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PDZD2 is annotated as secreted, so native PDZD2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label PDZD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PDZD2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...